Core Insights - ON Semiconductor is currently in the 17th phase of its 18-phase Adhishthana Cycle, indicating a potential lack of a major high in the near future [1] - The monthly chart shows ON in Phase 7, with a significant decline pausing just above the Nirvana level, suggesting a key support zone [10] Weekly Chart Analysis - The Guna Triads in phases 14, 15, and 16 are critical for determining the potential for achieving Nirvana, but ON shows no clear signs of a bullish move [4][5] - The absence of a bullish structure indicates that Phase 18, starting August 25, 2025, is unlikely to deliver a euphoric top [5] Monthly Chart Analysis - ON is in Phase 7, marked by a decline characterized by three strong red bars followed by sideways movement and additional red bars [8][9] - The decline halted at $31.04, just above the Nirvana level of $27.23, indicating a gravitational support level during downturns [9] Conclusion and Recommendations - The weekly chart suggests ON is unlikely to reach a new major high, while the monthly chart indicates a more optimistic outlook due to the stock's alignment with key support levels [10] - Existing investors can hold, as the long-term structure remains intact, while new entrants may consider waiting until the completion of Phase 18 to avoid stagnation [11]

Core Insights - Alnylam Pharmaceuticals (ALNY) is currently in Phase 10 of its 18-phase Adhishthana Cycle, with expectations for a peak formation in Phase 11, scheduled to end in September 2025 [1][5][6] Phase Analysis - The stock experienced a significant gap-up of over 30% on June 24 after positive results from its drug Vutrisiran for treating transthyretin amyloid cardiomyopathy, aligning with the principles of the Adhishthana framework [4][5] - Phase 9 was characterized by powerful structural shifts, leading to the current bullish stance in Phase 10, which is still building without signs of a peak [5][6] - Peak formation in Phase 10 typically occurs between the 18th and 23rd bars, but ALNY has not yet shown signs of this peak [6] Monthly Chart Insights - On the monthly chart, ALNY is in Phase 6, associated with the creation of a Nirvana level, projected to emerge around $240 by September 30, 2025 [9][10] - The stock has been forming its monthly Adhishthana Cakra since Phase 4 and is currently near the upper arc of this structure, indicating potential exhaustion as Phase 10 matures [10] Investor Outlook - Existing investors are advised to hold while monitoring for signs of structural breakdown, which would indicate a descent phase, referred to as the "Wrath of Ganga" [11] - New entrants are cautioned against entering during Phase 10 due to poor risk-reward dynamics, as the stock is trading near the higher arc of the monthly Adhishthana Cakra [12]

Core Viewpoint - Hilton Worldwide Holdings Inc. (HLT) is currently in the 17th phase of the 18-phase Adhishthana Cycle, indicating a potential bearish move before a final rally occurs [1] Guna Triads and Their Implications - Phases 14, 15, and 16 form the Guna Triads, which are critical in determining the nature of Phase 18 [2] - Phases 14 and 15 exhibited mild bullish strength (Satoguna) with rallies of approximately 23% and 26% respectively, while Phase 16 experienced a severe bearish energy (Tamoguna), resulting in a decline of nearly 28% [4] - A strong Tamoguna in Phase 16 suggests that Phase 18 will likely start with a significant bearish "death move" [4] Outlook for Phase 18 - HLT is in Phase 17, characterized as a no-action phase with low conviction, lasting until November 9, 2025 [5] - Following the transition to Phase 18 on November 10, 2025, a bearish "death move" is anticipated to occur between November 10, 2025, and May 10, 2026, potentially leading to a sharp correction [6] Investor Takeaway - Despite a long-term bullish structure, the near-term outlook for HLT remains weak due to the strong Tamoguna and the inertia of Phase 17, suggesting a breakdown is more likely than a breakout in the coming months [8] - Investors are advised to remain on the sidelines until the completion of the death move in Phase 18, with a more favorable risk-reward setup expected after May 2026 [8]

Core Viewpoint - Becton Dickinson and Company (BDX) is currently in the 17th phase of the 18-phase Adhishthana Cycle, indicating continued underperformance and consolidation until early June 2027 [1] Group 1: Adhishthana Cycle Analysis - BDX started its Adhishthana Cycle positively but experienced a critical shift entering Phase 8, where the expected bullish Cakra formation broke down [2][4] - The breakdown of the Cakra in Phase 8 led to over 1,400 days of sideways consolidation, confirming the structural weakness [6] - The Guna Triads, which assess the potential for reaching the highest price point in Phase 18, showed BDX's triads to be among the weakest compared to peers, lacking the necessary bullish momentum [9][10] Group 2: Monthly Chart and Future Outlook - On the monthly chart, BDX is in the Sankhya Period of Phase 2, characterized by bearish pressure and range-bound behavior, expected to last until August 2, 2027 [13] - The combination of the structural breakdown, weak Guna Triads, and bearish monthly trends suggests that BDX is not positioned for recovery in the near term [14][15]

Core Insights - Synopsys (SNPS) is currently in Phase 10 of its 18-phase Adhishthana Cycle, with indications that a peak may have already been reached, suggesting potential bearish trends in upcoming phases [1][8] Synopsys's Cycle So Far - From Phase 9, Synopsys experienced a significant rally, gaining approximately 223%, attributed to the "Supreme Move" phase as defined by Adhishthana Principles [4] - The stock has shown signs of a peak at the 18th bar of Phase 10, having corrected by around 20% from its high of $629.38 [5] Phase Durations - Phase 10 is set to conclude on August 2, 2026, with indications that SNPS may not reclaim its previous high within this timeframe [8] - The subsequent Phase 11 will commence on August 3, 2026, and extend until March 2, 2031 [7] Weekly Chart Outlook - On the weekly chart, Synopsys has entered Phase 9, typically associated with strong breakouts; however, the cakra built between Phases 4-8 was unsuccessful, leading to trading below the lower band, indicating potential underperformance [9]

Core Insights - Zscaler (ZS) is currently in the 10th Phase of its 18 Phase Adhishthana Cycle, having rallied approximately 33% since entering this phase [1] - The stock has shown a 66.66% alignment with the Adhishthana Principles, a framework for forecasting stock behavior through cyclical analysis [1] Phase Analysis - In Phase 2, Zscaler experienced a consolidation range with a bearish tilt for 37 bars, followed by a sharp bullish rally of roughly 225%, termed the Rally of Buddhi [2][4] - Phase 4 began at $191.14, with the stock reaching a high of $376.11, but this rally was deemed illusory, leading to a renunciation phase in Phase 5 where Zscaler dropped below the Phase 4 low of $125.12 [5] - Phase 6 established a Level of Nirvana at $146.93, which now serves as a key valuation barometer during bearish phases [7] Current and Future Outlook - Zscaler is in Phase 10, which often marks the beginning of an ascent towards the Adhishthana Himalayan Formation, with expectations of a peak formation occurring between the 18th and 23rd bars of Phase 10, translating to a window between 2 September and 12 October 2025 [10] - On the monthly timeframe, Zscaler is in Phase 2, having begun a classic Rally of Buddhi after consolidating for 38 bars, with this phase scheduled to end on 31 January 2028 [13] Investor Considerations - Zscaler did not deliver a significant move in Phase 9 on the weekly charts, which is typically expected, and its weekly alignment percentage is lower compared to some peers [16] - The company remains a strong hold, with investors advised to monitor the period from 2 September to 12 October 2025 for potential peak formation in Phase 10 [17]

Core Viewpoint - CrowdStrike is currently in its 8th Phase of the Adhishthana Cycle, and while the stock appears bullish, there are indications that recent gains may not be sustainable, warranting caution among investors [1][9]. Group 1: Current Position and Alignment - CrowdStrike has maintained an 85.71% alignment with the Adhishthana Principles, which forecast stock behavior through cyclical analysis [2]. - The stock is completing a Cakra, a curved bullish channel spanning Phases 4 through 8, which is expected to guide price movement until the end of Phase 8 [8][11]. Group 2: Key Structural Elements - In Phase 6, CrowdStrike established a Level of Nirvana at $286.11, which serves as a critical valuation anchor for future phases [5]. - The Cakra channel is currently respected, and a breakout above this channel during Phase 8 is deemed highly unlikely, with true breakouts expected in Phase 9 [11][12]. Group 3: Future Outlook - A retest of the lower boundary near the Nirvana level of $286.11 is likely before any decisive breakout occurs [13]. - Investors holding long positions should consider hedging their exposure, while new entrants may benefit from waiting for the stock to approach the Nirvana level for a more favorable entry point [13].

Core Insights - Regeneron Pharmaceuticals (REGN) has been in a downtrend for over 280 days, currently in the 10th Phase of its 18-Phase Adhishthana Cycle, indicating a significant structural breakdown rather than mere technical fluctuations [1][15]. Historical Performance - The current Adhishthana Cycle for Regeneron began on January 29, 2018, with the stock initially following expected market behaviors until Phase 9 [2]. - In Phase 2, Regeneron experienced a strong Rally of Buddhi, surging approximately 113% after a consolidation period of 37 bars [5]. - Phase 3 saw a slight rally followed by a rounded top, leading to a decline of about 33%, aligning with the Adhishthana framework [8]. - Phase 6 established a Nirvana Level at $671.41, which now serves as a valuation benchmark [10]. Phase 9 Breakdown - Phase 9 typically marks a breakout above the bullish "Cakra" channel, but Regeneron broke downwards, leading to a significant decline [13]. - This breakdown triggered the Move of Pralaya, resulting in a collapse of bullish sentiment and a stock price drop of approximately 54% since the break [14]. Future Outlook - Currently in Phase 10, Regeneron is in a state of structural limbo, with no meaningful recovery expected until it enters the Guna Triads (Phases 14, 15, and 16), which begin on February 7, 2028 [15]. - The current structure suggests continued weakness and uncertainty for the stock until the completion of the Guna Triads [15].

Core Insights - Thermo Fisher Scientific Inc. (TMO) is currently in the 18th and final phase of the Adhishthana Cycle across both weekly and monthly timeframes, indicating a transitional moment for the stock [3][12] - The stock has experienced a decline of 38% since entering the 18th phase, primarily due to bearish sentiment reflected in the weekly chart [6][10] - The monthly chart presents a contrasting narrative, suggesting potential for long-term upside, but the current weakness is driven by the bearish signals on the weekly chart [10][11] Weekly Chart Analysis - The Guna Triads for TMO in phases 14-16 were dominated by Rajoguna and Tamoguna, indicating indecision, volatility, and bearish sentiment [6][5] - The bearish 18th phase on the weekly chart is expected to continue until November 30, 2025, keeping the stock under pressure [10][11] - The 'Death Move' pattern suggests a significant correction after entering Phase 18 before potentially reaching Nirvana [10] Monthly Chart Analysis - The Guna Triads for the monthly chart in phases 14-16 were characterized by Satoguna, indicating a more constructive outlook [10] - The bullish signals on the monthly chart are anticipated to take precedence only after the conclusion of the bearish weekly phase in late 2025 [11] - The monthly Phase 18 does not conclude until July 31, 2030, suggesting long-term upside potential remains viable [12] Investment Strategy - Clients pursuing shorter timeframes have been implementing bearish spreads since the initiation of the weekly 18th phase [11] - A shift towards increased bullish exposure is expected post-2025 as the long-term value and Nirvana setup on the monthly chart becomes dominant [11] - TMO is positioned as a compelling candidate for patient investors looking to capitalize on deep-cycle insights, provided they time their investments appropriately [12]

Core Viewpoint - Blackstone Inc. is currently in the 6th Phase of its 18-Phase Adhishthana Cycle, with potential for value accumulation, but significant breakout may not occur until late 2026 [1][16]. Group 1: Current Cycle Analysis - Blackstone has completed one full 18-phase Adhishthana Cycle and is currently in its 6th cycle, which began on October 11, 2021, showing a 99% alignment with Adhishthana Principles [2][3]. - The stock is expected to revisit the low of the previous phase before moving higher, having already completed this retest, making current valuations attractive [6][12]. Group 2: Valuation Insights - The Level of Nirvana for Phase 6 will be confirmed on October 19, 2025, and if Blackstone remains below this level, it will be considered a long-term value play [7][13]. - The anticipated Level of Nirvana is estimated to settle around $129–$130, based on recent highs and potential price movements [13]. Group 3: Future Projections - Late 2026 is critical for Blackstone as it is expected to enter Phase 9 of its weekly Adhishthana Cycle, which is characterized by significant breakout potential [14][15]. - Current price levels suggest a solid long-term value case, with short-term corrections towards $104 being probable and healthy before a potential breakout [15][16].